Utilizing Biomarker Testing to Improve Lung Cancer Survival: Beth Sandy, MSN, CRNP

The survival rate for lung cancer has improved significantly in recent years, largely due to the adoption of biomarker testing and the development of targeted therapies. In this interview in honor of Lung Cancer Awareness Month, Beth Sandy, MSN, CRNP, Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, discusses the importance of utilizing biomarker testing in order to determine treatment options for patients with lung cancer. Oncology Data A...

Continue reading

New Opportunities in Advanced KRAS Mutation–Positive NSCLC With D. Ross Camidge, MD, PhD, and Beth Sandy, MSN, CRNP, OCN®

An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 84% of cases are classified as non-small cell. Most patients are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management (ACS, 2020). Although 70% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop progressive disease within 5 months of t...

Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.